Leading Life Science Publication SciBX Highlights RVX-208

"Most Advanced Epigenetic Drug in Clinical Development"

TSX Exchange Symbol: RVX

CALGARY, May 21, 2014 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced that its lead compound in clinical development, RVX-208, was prominently featured in the prestigious life science publication SciBX.  SciBX: Science-Business eXchange is a weekly publication that focuses on scientific acumen of Nature Publishing Group with the business intelligence of BioCentury Publications, Inc.  The report focused on the emerging class of BET inhibitors, all of which are Epigenetic drugs designed for a variety of important diseases with high unmet medical need including cancer and atherosclerosis vascular disease. RVX-208, a first in class BET-inhibitor, is currently being studied for potential use in high risk vascular disease patients such as acute coronary syndrome (ACS), type 2 diabetes (T2D), chronic kidney disease (CKD), and Dementia diseases including Alzheimer's Disease (AD).  

"We are very pleased to have a leading science publication SciBX provide commentary on the important and emerging class of Epigenetic drugs BET inhibitors," stated Donald McCaffrey President and Chief Executive Officer of Resverlogix. 

"RVX-208 is leading the way in Epigenetic drug development for vascular disease risk" stated Dr. Jan Johansson, Senior Vice President of Medical Affairs at Resverlogix. "These are very exciting times for BET inhibition and we continue to develop a more comprehensive understanding of how RVX-208 impacts multiple disease states to apply this knowledge to move this truly important small molecule forward in new and larger clinical trials soon," Dr. Johansson added.  

About SCI BX

SciBX: Science-Business eXchange is a weekly publication that unites the scientific acumen of Nature Publishing Group with the business intelligence of BioCentury Publications, Inc. to provide timely, concise and understandable analysis of the scientific content and commercial potential of the most important translational research papers with the potential to transform human therapeutics and diagnostics. By distilling the flood of life sciences literature down to the 25 key scientific developments each week, and providing in-depth analysis of the most important findings, SciBX provides a unique scientific and commercial perspective on today's breakthrough science.

About RVX-208

RVX-208 is a first-in-class small molecule that selectively inhibits BET bromodomains. RVX-208 functions by several mechanisms such as removing atherosclerotic plaque via reverse cholesterol transport (RCT), the natural process through which atherosclerotic plaque is transported out of the arteries and removed from the body by the liver. RVX-208 increases production of Apolipoprotein A-I (ApoA-I), the key building block of functional high-density lipoprotein (HDL) particles and the type required for RCT. These newly produced, functional HDL particles are flat and empty and can efficiently remove plaque and stabilize or reverse atherosclerotic disease. Analysis of recent clinical trials data showed that RVX-208 significantly reduces coronary atherosclerosis and major adverse cardiac events in patients with CVD who have a low level of HDL and elevated CRP, and other select populations with unmet medical need. ApoA-I enhancement and glucose lowering have been reported to exert beneficial effects in Alzheimer's disease, Diabetes Mellitus and chronic kidney disease (CKD). RVX-208 also has anti-inflammatory effects including effects on Interleukin-6 inhibition, vascular cell adhesion-1 and monocyte chemotactic protein-1, factors known to be involved in atherosclerosis and plaque stability.

About Resverlogix

Resverlogix Corp. (TSX:RVX) is a clinical stage cardiovascular company developing compounds involving a therapeutic increase in ApoA-I. Resverlogix's RVX-208 is a first-in-class small molecule for the treatment of atherosclerosis and other chronic diseases such as Diabetes Mellitus and Alzheimer's disease. RVX-208 is the first BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities and the potential role of RVX-208 in the treatment of atherosclerosis. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contacts:

Donald J. McCaffrey

Kenneth Lebioda                                  

President and CEO

SVP Business & Corporate Development                      

Resverlogix Corp.

Resverlogix Corp.                                            

Phone: 403-254-9252

Phone: 403-254-9252

Email: don@resverlogix.com

Email: ken@resverlogix.com


SOURCE: Resverlogix Corp.


Profil de l'entreprise

Resverlogix Corp.

Renseignements sur cet organisme


Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .


Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.


Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.